Tech Company Financing Transactions
23andMe Funding Round
23andMe, based in Mountain View, secured $300 million from GlaxoSmithKline.
Transaction Overview
Company Name
Announced On
7/26/2018
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The 23andMe deal won't yield new products overnight but new R&D head Hal Barron says it will accelerate GSK's drug development work, which has lagged behind rivals in producing multibillion-dollar blockbuster drugs.
Company Information
Company Status
Private & Independent
Industry
Enterprise IT
Mailing Address
1390 Shorebird Way
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Overview
23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anne Wojcicki
Chief Financial Officer
Steve Schoch
Chief Information Officer
David Baker
Chief Technical Officer
Michael Polcari
Vice President
Arnab Chowdry
Vice President
Okey Onyejekwe
VP - Engineering
Steve Lemon
VP - General Counsel
Kathy Hibbs
VP - Human Resources
Fred Kohler
VP - Marketing
Tracy Keim
VP - Marketing
Katie Watson
VP - R & D
Joyce Tung
Browse more venture capital transactions:
Prev: 7/26/2018: Tally venture capital transaction
Next: 7/26/2018: Platform Science venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs